Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    Baricitinib Shows Promise as Potential New Treatment for Rheumatoid Arthritis, Study Shows
    October 7, 2016October 7, 2016

    Baricitinib Shows Promise as Potential New Treatment for Rheumatoid Arthritis, Study Shows

    News
    Treatment with baricitinib improves joint damage in patients with rheumatoid arthritis (RA) who have an inadequate response or intolerance to conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), according to the results of ... Read more
    Stimulating Environment Boosted Immune System in Mice; RA applications envisioned
    October 5, 2016October 5, 2016

    Stimulating Environment Boosted Immune System in Mice; RA applications envisioned

    News
    It may be possible to boost the immune system simply by staying in a stimulating environment, according to a study that showed giving mice more toys and space for two ... Read more
    Potential RA Therapy, CT-P10, Seen in Study to Be Biosimilar to Rituxan
    October 3, 2016October 3, 2016

    Potential RA Therapy, CT-P10, Seen in Study to Be Biosimilar to Rituxan

    News
    In a Phase 1 clinical trial, researchers showed that CT-P10 is a biosimilar to Rituxan (rituximab), a current treatment of choice for rheumatoid arthritis (RA) patients who fail to respond to ... Read more
    Non-TNF Therapy Seen as Best for Rheumatoid Arthritis Patients Who Don’t Respond to Anti-TNF Treatment
    September 30, 2016September 30, 2016

    Non-TNF Therapy Seen as Best for Rheumatoid Arthritis Patients Who Don’t Respond to Anti-TNF Treatment

    News
    Non-tumor necrosis factor (TNF) drugs are more effective than anti-TNF drugs in some patients with rheumatoid arthritis, according to the results of a clinical trial that were published in the ... Read more
    European Medicines Agency Issues Positive Opinion for Cimzia AutoClicks Prefilled Pen
    September 28, 2016September 28, 2016

    European Medicines Agency Issues Positive Opinion for Cimzia AutoClicks Prefilled Pen

    News
    UCB announced that its Cimzia (certolizumab pegol) AutoClicks Prefilled Pen has been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). The CHMP positive opinion designation concerning ... Read more
    GSK Submits Rheumatoid Arthritis Treatment Sirukumab for EU Marketing Authorization
    September 26, 2016September 26, 2016

    GSK Submits Rheumatoid Arthritis Treatment Sirukumab for EU Marketing Authorization

    News
    GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product sirukumab, a subcutaneous formulation for adults with moderate to severe rheumatoid arthritis (RA). The ... Read more
    EU Commission Approves Orencia for RA Patients in Combination with Methotrexate
    September 23, 2016September 23, 2016

    EU Commission Approves Orencia for RA Patients in Combination with Methotrexate

    News
    The European Commission has approved the use of Orencia (abatacept) by intravenous infusion and injection in combination with methotrexate (MTX) to treat highly active and progressive rheumatoid arthritis (RA) in ... Read more
    AANP Asks Patients and Providers Alike to Ensure Chronic Pain Is Properly Treated
    September 12, 2016September 12, 2016

    AANP Asks Patients and Providers Alike to Ensure Chronic Pain Is Properly Treated

    News
    The American Association of Nurse Practitioners (AANP) is asking patients and healthcare providers alike to help stop chronic pain from being insufficiently treated by improving patient-provider communication, and by working to strengthen awareness ... Read more
    Investigational Treatment Improves Refractory Rheumatoid Arthritis in Clinical Study
    September 7, 2016September 7, 2016

    Investigational Treatment Improves Refractory Rheumatoid Arthritis in Clinical Study

    News
    Mesoblast Limited’s mesenchymal precursor cell (MPC) product candidate MPC-300-IV is well tolerated and results in a dose-dependent improvement in clinical symptoms, physical function, and disease activity in patients with refractory rheumatoid ... Read more
    Erelzi, a Biosimilar to Enbrel, Approved by FDA for Rheumatoid Arthritis, Other Inflammatory Diseases
    September 2, 2016September 2, 2016

    Erelzi, a Biosimilar to Enbrel, Approved by FDA for Rheumatoid Arthritis, Other Inflammatory Diseases

    News
    The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Erelzi (etanercept-szzs) for a number of inflammatory diseases, including rheumatoid arthritis (RA). Erelzi, a TNF inhibitor, was approved as a biosimilar to ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.